DRKS00000294已完成1 期
Phase I study of a gene modified, B7/IL-7-transfected allogeneic tumor cell vaccine for the treatment of metastatic renal cell carcinoma -
Medizinische Klinik für Hämatologie, Onkologie Charité, Campus Virchow0 个研究点目标入组 10 人开始时间: 2010年3月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •histologically proven renal cell carcinoma
- •-age between 18 and 75
- •-HLA-A0201-positive patients
- •-adequate performance status
- •-life expectancy over 3 months
- •-interval to last therapy >4 weeks
- •-one evaluable marker lesion
- •-written informed consent
排除标准
- •-pregnancy oder nursing, missing contraception
- •-evidence of autoimmune disease
- •-history of severe allergy
- •-systemic corticosteroid therapy or other immunosuppressive therapy
- •-patients with organ allografts
- •-HIV positivity
- •-active infection or severe disease
- •-active brain lesions
- •-impaired renal-, liver - oder hematological function
- •-evidence or history of malignant disease in the past five years
- •-use of unapproved biologic agents (mistletoe, live cells)
研究者
相似试验
已完成
1 期
Phase I study of a gene modified, B7/IL-2 transfected allogeneic tumor cell vaccine for the treatment of metastatic renal cell carcinomaC64Malignant neoplasm of kidney, except renal pelvisDRKS00000249udwig-Maximilians-Universität MünchenLabor für Tumorimmunologie, LIFE-Zentrum15
进行中（未招募）
1 期
Gene Therapy Trial in adults with Inherited Blistering Skin DiseaseRecessive Dystrophic Epidermolysis BullosaMedDRA version: 18.1Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-004884-19-GBKing's College London10
Unknown
1 期
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)Leukemia, Myeloid, AcuteMyelodysplastic SyndromesNCT02493829King's College London10
已完成
1 期
Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral TreatmentHIVHIV InfectionsNCT00105417National Institute of Allergy and Infectious Diseases (NIAID)20
已完成
1 期
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/IIChronic Myelogenous Leukemia, BCR-ABL1 PositiveCord Blood Transplant RecipientMyeloproliferative NeoplasmAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT03941769M.D. Anderson Cancer Center1